Fondamentix
返回排名列表

MoonLake Immunotherapeutics (MLTX)

被低估
HealthcareBiotechnologySwitzerland

基本面

32

价格

$11.57

市值

$996M

Yahoo FinanceTradingView新闻官网

第一部分 · 这家公司值多少

概览

MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.

No editorial profile for this company yet

Direct competitors

Who this company fights with for the same customers

Compare

Generated on 2026年9月19日 with claude-haiku-4-5 — shared with all users

AbbVie IncABBV
P/E: 73.9Score: 71Market cap: $470.55B

AbbVie's adalimumab (Humira) was the first biologic approved for hidradenitis suppurativa and still defines first-line treatment, while its risankizumab (Skyrizi) competes in psoriatic arthritis — both were used as active reference arms in MoonLake's own trials.

Eli Lilly and CompanyLLY
P/E: 38.8Score: 74Market cap: $1.11T

Lilly's ixekizumab (Taltz) is an IL-17A inhibitor prescribed for psoriatic arthritis, axial spondyloarthritis and plaque psoriasis, the rheumatology and dermatology indications sonelokimab is being developed for beyond hidradenitis suppurativa.

Incyte CorporationINCY
P/E: 17.1Score: 79Market cap: $24.86B

Incyte is bringing povorcitinib, an oral JAK1 inhibitor, through late-stage trials in hidradenitis suppurativa, competing for the same patients with a pill rather than an injection.

UCB S.A.UCB

UCB's bimekizumab (Bimzelx) blocks the same IL-17A and IL-17F cytokines as sonelokimab and is already approved for hidradenitis suppurativa and psoriatic arthritis, the two indications MoonLake is bringing to market.

Novartis AGNVS

Novartis sells secukinumab (Cosentyx), the IL-17A inhibitor approved in 2023 for hidradenitis suppurativa and widely used in psoriatic arthritis and axial spondyloarthritis, addressing the same dermatology and rheumatology prescribers MoonLake targets.

信息来源: MoonLake Immunotherapeutics — Form 10-K, fiscal year 2024MoonLake Immunotherapeutics Reports Third Quarter 2025 Financial Results and Announces New Data from Clinical Trials of its Nanobody SonelokimabNew HS Treatments: Latest FDA-Approved Options

资产负债表与流动性

营收

0

截至2025/12/31的财政年度

净利润

$-227M

截至2025/12/31的财政年度

自由现金流

$-196M

股东权益合计

$304M

负债合计

$120M

流动比率

12.56

利息覆盖率

26.58

债务/EBITDA

-

每股收益

营收与净利润

自由现金流

收入构成

暂无收入数据

历史财务表

利润率变化

债务变化

债务负担有多重

增长一览表

增长 — 营业收入

公允价值估算

无营收阶段被低估

公允价值

$28.54

当前价格

$11.57

安全边际

+59.5%

公允价值区间

$27.11 - $29.97

所用估值方法之间的离散区间，并非经过统计校准的置信区间。

估算方法

分析师目标价:$28.54
现金流折现法（DCF）:不适用于此类公司
市盈率法（P/E）:不适用于此类公司
格雷厄姆成长公式:不适用于此类公司
盈利能力价值（EPV）:不适用于此类公司
合理市净率（P/B）:不适用于此类公司
股息折现模型（戈登模型）:不适用于此类公司
P/FFO（运营资金）:不适用于此类公司
周期中段收益:不适用于此类公司
市销率法（P/S）:数据不足，无法计算
分析师共识:买入 (17B / 3H / 2S)
最近财报超预期:+10.35%

估值指标

市盈率（P/E）

-

ROE

-74.7%

市净率（P/B）

2.33

P/FCF

-

毛利率

-

ROIC

-40.1%

盈利能力雷达图

价值创造（经济护城河）

ROIC

-40.1%

WACC

10.3%

ROIC − WACC

-50.4 pp

ROIC 低于资本成本：公司每投入一美元都在毁灭价值。

基本面分析标准

通过（7）

  • P/B Ratio 2.33
  • Debt/Equity ratio
  • Current Ratio
  • Interest Coverage
  • Low reliance on intangibles
  • Analyst Consensus 77% Buy
  • Share Dilution 2.3%

未通过（9）

  • EPS shows upward trend
  • Price CAGR 2.13%
  • ROIC -40.1%
  • Positive Free Cash Flow
  • Return on Tangible Assets
  • DCF valuation (Unknown)
  • ROE -82.7%
  • Earnings Surprise avg -2.8%
  • Piotroski F-Score 1/9

不可用（11）

  • Gross Margin NaN%
  • P/FCF NaN
  • Dividend Payout NaN%
  • Operating Margin NaN%
  • CapEx intensity
  • Debt/EBITDA
  • Price below Graham Number
  • Revenue Growth 5Y (Finnhub)
  • PEG Ratio (need PE > 0 and growth > 0)
  • Earnings Quality (OCF/Net Income)
  • Net Margin Trend (invalid data)

Piotroski F-评分

1/9

存在严重财务隐患

score
criteria

盈利质量

-

低质量：需深入审查会计处理

股权稀释

2.3%

正在发行新股，稀释所有权

机构持股

公司治理

管理团队

姓名职位年龄
Dr. Jorge Santos da Silva Ph.D.Co-Founder, Interim Chair of the Board & CEO48
Dr. Kristian Reich M.D., Ph.D.Co-Founder & Chief Scientific Officer59
Mr. Matthias BodenstedtChief Financial Officer37
Mr. Oliver Daltrop Ph.D.Chief Technical Officer-
Ms. Carla BretesDirector of Investor Relations & External Communications-
Mr. Nicolas Mosimann Ph.D.General Counsel-
Joana CortezAssociate Vice-President of Legal & Compliance-
Tino AnthamattenVice President of Marketing, Market Access & Pricing-
Luciana MarquesAssociate Vice-President of HR, People and Culture-
Ms. Nuala BrennanChief Clinical Development Officer-

第二部分 · 价格与买入时机

这一部分不判断公司是否值得拥有：它帮助你在基本面说服你之后，选择何时买入。包含：技术分析、潜力、历史回撤、Gamma 敞口。

文件

  • 年度报告（10-K）

    对公司业务、财务业绩和风险的年度概述。

    提交日期：2026-02-25

    查看文件

  • 季度报告（10-Q）

    最近三个月财务表现的最新情况。

    提交日期：2026-08-10

    查看文件

  • 临时报告（8-K）

    关于重大事件（如管理层变动或重要公告）的通知。

    提交日期：2026-09-30

    查看文件

via SEC EDGAR

损益历史

via SEC EDGAR

Latest News

Recent headlines for MLTX, sourced from Markets Gazette.

  • 3/30/2026POSITIVE
    MoonLake Says Lead Drug Shows Durable Response, Eyes FDA Filing

    MoonLake Immunotherapeutics announced promising Phase 3 results for its lead drug in Hidradenitis Suppurativa (HS), showing a 62% HiSCR75 response rate at Week 40. This durable response rate suggests strong efficacy. Crucially, the company received feedback from the FDA that supports a potential path to filing without requiring additional trials. This significantly de-risks the development timeline and accelerates the path to market. Investors are likely to view this news favorably, anticipating a potential new treatment option and a strong commercial opportunity.

via Markets Gazette